In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vectura Group PLC

www.vectura.com

Latest From Vectura Group PLC

For Novartis' Generic Advair, Another 18 Months Was Too Far Into The Unknown

Company did not kill its development program because of US FDA feedback, but the experience seems to be another lesson in the difficulty in gaining approval for complex generics.

Generic Drugs Respiratory

Sandoz Will Not Pursue US Advair Rival

Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.

Strategy Generic Drugs

People Round-Up: Saraf Heads Amneal's Corporate Development As Butti Manages Italy For Stada

Apurva Saraf heads up corporate development for Amneal, Salvatore Butti becomes Stada’s general manager in Italy and Vectura searches for a new CEO.

Appointments Strategy

Vectura Prevails In US Litigation Over GSK’s Ellipta

Vectura has won an award of almost $90m after convincing a Delaware jury that GSK’s Ellipta respiratory range infringed one of its US patents. The firm currently has a development deal with Hikma for generic versions.

Legal Issues Generic Drugs
See All

Company Information

UsernamePublicRestriction

Register